Enzymes for Biomedical Use

Fiscal

2022 AGM

25-January 2023

1

Agenda

1. Official Business:

  1. Scrutineer's Report
  2. Approval of Minutes of the last Shareholders' Meeting
  3. Presentation of the Annual Report
    1. Election of the Directors
    2. Appointment of the Auditors
  2. Presentation on the Company Operations
  3. Question and Answers
  4. Results of the Ballots
  5. Termination of the Meeting

2

Forward-lookingStatements

Caution concerning forward-looking statements

This presentation may contain forward-looking statements based on current expectations of management. Any forward-looking statements inherently involve numerous risks and uncertainties, known and unknown. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Please refer to the Company's regulatory filings for more information concerning risks and uncertainties. IBEX disclaims obligation to update these forward-looking statements.

3

Business Focus

Manufacturing and sale of proprietary enzymes for clinical diagnostics

Manufacturing and sale of glycosaminoglycan "(GAG") enzymes for the research community

Contract manufacturing of reagents for third parties

4

Quality Management System

ISO 13485:2016

IBEX Quality Management System

is certified for the manufacture and sale of protein reagents and reagent- filled medical diagnostic device components

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Ibex Technologies Inc. published this content on 25 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 January 2023 09:03:10 UTC.